Blockchain Registration Transaction Record

Sapu Nano's Breast Cancer Therapy Clears Ethics Hurdle for Human Trials

Sapu Nano, an Oncotelic venture, receives HREC approval for Sapu003 breast cancer trials using innovative Deciparticle technology for intravenous everolimus delivery.

This development represents a potential breakthrough in breast cancer treatment by addressing the absorption limitations of existing oral everolimus formulations. For patients facing advanced breast cancer, improved drug delivery could mean more effective tumor control and better quality of life outcomes. The intravenous administration method may provide more consistent dosing and potentially stronger therapeutic effects, which could translate to improved survival rates and treatment efficacy. From an investment perspective, this milestone demonstrates Oncotelic's progress in advancing its pipeline and validates the potential of their proprietary Deciparticle technology platform, which could have broader applications across oncology therapeutics.